HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 342 filers reported holding HALOZYME THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.30 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,199,250 | +5.0% | 83,750 | -0.8% | 0.01% | +12.5% |
| Q2 2023 | $3,045,787 | +5.9% | 84,441 | +12.1% | 0.01% | +14.3% |
| Q1 2023 | $2,876,471 | +69179.2% | 75,320 | +3.2% | 0.01% | -36.4% |
| Q4 2022 | $4,152 | -99.9% | 72,978 | +1.2% | 0.01% | +37.5% |
| Q3 2022 | $2,851,000 | -8.4% | 72,114 | +2.0% | 0.01% | -11.1% |
| Q2 2022 | $3,111,000 | +16.4% | 70,688 | +5.5% | 0.01% | +28.6% |
| Q1 2022 | $2,672,000 | +11.5% | 67,022 | +12.4% | 0.01% | +16.7% |
| Q4 2021 | $2,397,000 | +0.2% | 59,607 | +1.3% | 0.01% | 0.0% |
| Q3 2021 | $2,393,000 | +21.3% | 58,838 | +35.5% | 0.01% | +20.0% |
| Q2 2021 | $1,972,000 | +56.0% | 43,420 | +43.2% | 0.01% | +25.0% |
| Q1 2021 | $1,264,000 | +29.2% | 30,323 | +32.4% | 0.00% | +33.3% |
| Q4 2020 | $978,000 | +205.6% | 22,900 | +91.7% | 0.00% | +200.0% |
| Q2 2020 | $320,000 | – | 11,948 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,305,403 | $233,209,000 | 10.86% |
| BB BIOTECH AG | 7,379,832 | $89,148,000 | 3.13% |
| SENZAR ASSET MANAGEMENT, LLC | 550,544 | $6,650,572,000 | 1.72% |
| SNYDER CAPITAL MANAGEMENT L P | 2,232,114 | $26,964,000 | 1.69% |
| Sterling Global Strategies LLC | 22,000 | $266,000 | 0.98% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,290,024 | $112,223,000 | 0.98% |
| MSD Partners, L.P. | 965,000 | $11,657,000 | 0.94% |
| DOHENY ASSET MANAGEMENT /CA | 130,950 | $1,582,000 | 0.81% |
| Taylor Wealth Management Partners | 128,110 | $1,548,000 | 0.69% |
| Bellevue Group AG | 318,000 | $3,841,000 | 0.69% |